
In this Review, the authors discuss the use of immune-checkpoint inhibitors for treatment of cancer in patients with pre-existing autoimmune disease, including the possibility of the use of biologic DMARDs to enhance tumour responses while preventing severe immune-related adverse events.
Like
Save
Share